<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689936</url>
  </required_header>
  <id_info>
    <org_study_id>CC-5013-MM-020</org_study_id>
    <secondary_id>2007-004823-39</secondary_id>
    <nct_id>NCT00689936</nct_id>
  </id_info>
  <brief_title>Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma</brief_title>
  <acronym>FIRST</acronym>
  <official_title>A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-week Cycles in Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose
      dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CC-5013-MM020/IFM 07-01 is a Phase III, multicenter, randomized, open-label, 3-arm study that
      will compare the efficacy and safety of two Lenalidomide plus low-dose dexamethasone regimens
      given for two different durations of time (i.e., until progressive disease [PD] or for up to
      a maximum of 18 four-week cycles) to that of MPT given for a maximum of 12 six-week cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 21, 2008</start_date>
  <completion_date type="Actual">July 14, 2016</completion_date>
  <primary_completion_date type="Actual">July 14, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)</measure>
    <time_frame>From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.</time_frame>
    <description>PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis</measure>
    <time_frame>From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months</time_frame>
    <description>PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS)</measure>
    <time_frame>From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 48.3 months</time_frame>
    <description>Overall survival was defined as the time between randomization and death. Participants, who died, regardless of the cause of death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the participant was known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Objective Response Based on IRAC Review</measure>
    <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
    <description>Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined as: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Objective Response Based on Investigator Assessment at Time of Final Analysis</measure>
    <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
    <description>Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimates of Duration of Myeloma Response as Determined by the IRAC</measure>
    <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median follow-up for responders was 20.1 months</time_frame>
    <description>Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimates of Duration of Myeloma Response as Determined by an Investigator Assessment at Time of Final Analysis</measure>
    <time_frame>Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median follow-up for responders was 19.9 months</time_frame>
    <description>Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Response Based on the Review by the IRAC</measure>
    <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
    <description>The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Response Based on the Investigator Assessment at the Time of Final Analysis</measure>
    <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm.</time_frame>
    <description>The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimates of Time to Treatment Failure (TTF)</measure>
    <time_frame>From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 16.1 months.</time_frame>
    <description>TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by IRAC based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimates of Time to Treatment Failure (TTF) at the Time of Final Analysis</measure>
    <time_frame>From date of randomization until the data cut-off date of 21 January 2016; median follow up for all participants was 16.1 months.</time_frame>
    <description>TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by the investigators assessment based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimates for Time to Second-line Anti-myeloma Treatment (AMT)</measure>
    <time_frame>From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 23.0 months</time_frame>
    <description>Time to second-line anti-myeloma therapy was defined as time from randomization to the start of another non-protocol anti-myeloma therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimates of Time to Second Line Therapy AMT at the Time of Final Analysis</measure>
    <time_frame>From date of randomization until the data cut-off of date 21 January 2016; median follow-up for all participants was 23.0 months</time_frame>
    <description>Time to second-line anti-myeloma therapy is defined as time from randomization to the start of another non-protocol anti-myeloma therapy. Those who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Objective Response After Second-line Anti-myeloma Treatment at the Time of Final Analysis</measure>
    <time_frame>Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
    <description>Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Myeloma Response by Adverse Risk Cytogenetic Risk Category Based on IRAC Review.</measure>
    <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
    <description>Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Myeloma Response by Favorable Hyperdiploidy Risk Cytogenetic Risk Category Based on IRAC Review</measure>
    <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
    <description>Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Myeloma Response by Normal Risk Cytogenetic Risk Category Based on IRAC Review</measure>
    <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
    <description>Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Myeloma Response by Uncertain Risk Cytogenetic Risk Category Based on IRAC Review</measure>
    <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
    <description>Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain</measure>
    <time_frame>Cycle 1 Day 1, (Baseline) then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EORTC QLQ-C30 Fatigue Domain</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EORTC QLQ-C30 Pain Domain</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EORTC QLQ-C30 Nausea/Vomiting Domain</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EORTC QLQ-C30 Dyspnea Domain</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EORTC QLQ-C30 Insomnia Domain</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Scale is scored between 0 and 100, with a high score indicating a higher level of appetite loss. Negative change from Baseline values indicate improvement in appetite and positive values indicate worsening of appetite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EORTC QLQ-C30 Constipation Domain</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale is scored between 0 and 100, with a high score indicating a higher level of constipation. Negative change from Baseline values indicate improvement in constipation and positive values indicate worsening of constipation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EORTC QLQ-C30 Diarrhea Domain</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100, with a high score indicating a higher level of diarrhea. Negative change from Baseline values indicate improvement in diarrhea and positive values indicate worsening of diarrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EORTC QLQ-C30 Financial Difficulties Domain</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Difficulties Scale is scored between 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicate improvement in financial difficulties and positive values indicate worsening of financial difficulties.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score indicates more severe disease symptom(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Side Effects Treatment Scale</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score represents a more severe overall side effect of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the future perspective scale, a higher score indicates a better perspective of the future.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Body Image Scale</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the body image scale, a higher score indicates a better body image.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Health Utility Index Score</measure>
    <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
    <description>EQ-5D is a self-administered questionnaire that assesses health-related quality of life. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where higher EQ-5D scores represent better health status. A positive change from baseline score indicates improvement in health status and better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year</measure>
    <time_frame>Day 1 (randomization) up to last visit completed 25 July 2016</time_frame>
    <description>HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective. The rate of inpatient hospitalizations per patient year was calculated as the total number of hospitalizations divided by the total number of patient-years followed in the study period. Patient-years (PY) were calculated as the duration from baseline to last available HRQL assessment for each patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) During the Active Treatment Phase</measure>
    <time_frame>From first dose of study drug through 28 days following the discontinuation visit from active treatment phase; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
    <description>A TEAE is any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shift From Baseline to Most Extreme Postbaseline Value in Creatinine Clearance (CrCl) During the Active Treatment Phase</measure>
    <time_frame>Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
    <description>Renal function was assessed for participants from baseline to the most extreme value in creatinine clearance calculated using the Cockcroft-Gault estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shift From Baseline to Most Extreme Postbaseline Value in Absolute Neutrophil Count During the Active Treatment Phase</measure>
    <time_frame>Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
    <description>Neutrophil counts was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shift From Baseline to Most Extreme Postbaseline Value in Hemoglobin During the Active Treatment Phase</measure>
    <time_frame>Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
    <description>Hemoglobin was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shift From Baseline to Most Extreme Postbaseline Value in Platelet Count During the Active Treatment Phase.</measure>
    <time_frame>Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
    <description>Improvement in platelets was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Infection Rate by Observing the Historical Data Compared to the Clinical Data Base</measure>
    <time_frame>From randomization to 24 May 2013</time_frame>
    <description>Improvement of infection rate by observing historical data compared to the data within clinical database as not analyzed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1623</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide / Dexamethasone until disease progression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide plus low-dose dexamethasone given until disease progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenalidomide / Dexamethasone for 18 cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination of Melphalan, Prednisone and Thalidomide given for 12 six-week cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide and low-dose dexamethasone</intervention_name>
    <description>Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD.
Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression</description>
    <arm_group_label>Lenalidomide / Dexamethasone until disease progression</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles</intervention_name>
    <description>lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles.
Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles</description>
    <arm_group_label>Lenalidomide / Dexamethasone for 18 cycles</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan, Prednisone and Thalidomide</intervention_name>
    <description>Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles</description>
    <arm_group_label>Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles</arm_group_label>
    <other_name>Prednisone</other_name>
    <other_name>Thalomid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must understand and voluntarily sign informed consent form

          2. Age ≥ 18 years at the time of signing consent

          3. Previously untreated, symptomatic multiple myeloma as defined by the 3 criteria below:

               -  MM diagnostic criteria (all 3 required):

               -  Monoclonal plasma cells in the bone marrow ≥10% and/or presence of a
                  biopsy-proven plasmacytoma

               -  Monoclonal protein present in the serum and/or urine

               -  Myeloma-related organ dysfunction (at least one of the following) [C] Calcium
                  elevation in the blood (serum calcium &gt;10.5 mg/dl or upper limit of normal) [R]
                  Renal insufficiency (serum creatinine &gt;2 mg/dl) [A] Anemia (hemoglobin &lt;10 g/dl
                  or 2 g &lt; laboratory normal) [B] Lytic bone lesions or osteoporosis

             AND have measurable disease by protein electrophoresis analyses as defined by the
             following:

               -  IgG multiple myeloma: Serum monoclonal paraprotein (M-protein) level ≥ 1.0 g/dl
                  or urine M-protein level ≥ 200 mg/24 hours

               -  IgA multiple myeloma: Serum M-protein level ≥ 0.5 g/dl or urine M-protein level ≥
                  200 mg/24 hours

               -  IgM multiple myeloma (IgM M-protein plus lytic bone disease documented by
                  skeletal survey plain films): Serum M-protein level ≥ 1.0 g/dl or urine M-protein
                  level ≥ 200mg/24hours

               -  IgD multiple myeloma: Serum M-protein level ≥ 0.05 g/dl or urine M-protein level
                  ≥ 200 mg/24 hours

               -  Light chain multiple myeloma: Serum M-protein level ≥ 1.0 g/dl or urine M-protein
                  level ≥ 200 mg/24 hours

             AND are at least 65 years of age or older or, if younger than 65 years of age, are not
             candidates for stem cell transplantation because:

               -  The patient declines to undergo stem cell transplantation or

               -  Stem cell transplantation is not available to the patient due to cost or other
                  reasons

          4. ECOG performance status of 0, 1, or 2

          5. Able to adhere to the study visit schedule and other protocol requirements

          6. Females of child-bearing potential (FCBP)^2:

               1. Must agree to undergo two medically supervised pregnancy tests prior to starting
                  study therapy with either Rd or MPT. The first pregnancy test will be performed
                  within 10-14 days prior to the start of Rd or MPT and the second pregnancy test
                  will be performed within 24 hours prior to the start of Rd or MPT. She must also
                  agree to ongoing pregnancy testing during the course of the study and after the
                  end of study therapy. This applies even if the patient practices complete and
                  continued sexual abstinence.

               2. Must commit to either continued abstinence from heterosexual intercourse (which
                  must be reviewed on a monthly basis) or agree to use and be able to comply with
                  effective contraception without interruption, 28 days prior to starting study
                  drug, during the study therapy (including during periods of dose interruptions),
                  and for 28 days after discontinuation of study therapy.

          7. Male Patients:

               1. Must agree to use a condom during sexual contact with a FCBP, even if they have
                  had a vasectomy, throughout study drug therapy, during any dose interruption and
                  after cessation of study therapy.

               2. Must agree to not donate semen during study drug therapy and for a period after
                  end of study drug therapy.

               3. Must practice complete abstinence or agree to use a condom during sexual contact
                  with a pregnant female or a female of childbearing potential while participating
                  in the study, during dose interruptions and for at least 28 days following study
                  drug discontinuation, even if he has undergone a successful vasectomy.

          8. All patients must:

               1. Have an understanding that the study drug could have a potential teratogenic
                  risk.

               2. Agree to abstain from donating blood while taking study drug therapy and
                  following discontinuation of study drug therapy.

               3. Agree not to share study medication with another person. All FCBP and male
                  patients must be counseled about pregnancy precautions and risks of fetal
                  exposure.

        Exclusion Criteria:

          1. Previous treatment with anti-myeloma therapy (does not include radiotherapy,
             bisphosphonates, or a single short course of steroid [i.e., less than or equal to the
             equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid
             treatment must not have been given within 14 days of randomization]).

          2. Any serious medical condition that places the patient at an unacceptable risk if he or
             she participates in this study. Examples of such a medical condition are, but are not
             limited to, patient with unstable cardiac disease as defined by: Cardiac events such
             as MI within the past 6 months, NYHA heart failure class III-IV, uncontrolled atrial
             fibrillation or hypertension; patients with conditions requiring chronic steroid or
             immunosuppressive treatment, such as rheumatoid arthritis, multiple sclerosis and
             lupus, that likely need additional steroid or immunosuppressive treatments in addition
             to the study treatment.

          3. Pregnant or lactating females.

          4. Any of the following laboratory abnormalities:

               -  Absolute neutrophil count (ANC) &lt; 1,000/µL (1.0 x 109/L)

               -  Untransfused platelet count &lt; 50,000 cells/µL (50 x 10^9/L)

               -  Serum SGOT/AST or SGPT/ALT &gt; 3.0 x upper limit of normal (ULN)

          5. Renal failure requiring hemodialysis or peritoneal dialysis.

          6. Prior history of malignancies, other than multiple myeloma, unless the patient has
             been free of the disease for ≥ 3 years. Exceptions include the following:

               -  Basal cell carcinoma of the skin

               -  Squamous cell carcinoma of the skin

               -  Carcinoma in situ of the cervix

               -  Carcinoma in situ of the breast

               -  Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)

          7. Patients who are unable or unwilling to undergo antithrombotic therapy.

          8. Peripheral neuropathy of &gt; grade 2 severity.

          9. Known HIV positivity or active infectious hepatitis, type A, B, or C. Primary AL
             (immunoglobulin light chain) amyloidosis and myeloma complicated by amyloidosis.

               -  1 A variety of other types of end organ dysfunctions can occasionally occur and
                  lead to a need for therapy. Such dysfunction is sufficient to support
                  classification as myeloma if proven to be myeloma-related.

               -  2 A FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or
                  bilateral oophorectomy or 2) has not been naturally postmenopausal (i.e.,
                  amenorrhea following cancer therapy does not rule out childbearing potential) for
                  at least 24 consecutive months (i.e., has had menses at any time in the preceding
                  24 consecutive months).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Jacques, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of AL Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar Sinai Medical Center Dept of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco- California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Stanford</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gainesville Heme Oncology Associates</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Oncology</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Cancer Institute, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois Hematology Oncology</name>
      <address>
        <city>Centralia</city>
        <state>Illinois</state>
        <zip>62801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orchard Healthcare Research, Inc.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John H Stroger Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Cancer Institute</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426-3558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Center for Cancer Medicine Blood Disorders</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arena Oncology Associates, PC</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dakota Cancer Institute</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest Oncology Hematology</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital and Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Center</name>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <zip>38017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Cancer Institute</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0561</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre Divsion of Haematology Medical Oncology</name>
      <address>
        <city>E. Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Hospital</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geelong Hospital</name>
      <address>
        <city>Geelong</city>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Gosford</city>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital</name>
      <address>
        <city>Malvern</city>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Hospital</name>
      <address>
        <city>Southport</city>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Wentworthville</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Wodonga</city>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wollongong Hospital</name>
      <address>
        <city>Wollongong</city>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Leoben</name>
      <address>
        <city>Leoben</city>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Barmherzige Schwestern Linz</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Elisabethinen Linz</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Linz</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MM-015. Salzburger Landkliniken, St. Johanns-Spital, Universitätsklinik fur Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital St. Polten</name>
      <address>
        <city>St. Pölten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the Barmherzigen Bruder Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MM-015.Wihelminenspital</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MM-015. Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Wels</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Wiener Neustadt</name>
      <address>
        <city>Wiener Neustadt</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg Centrumziekenhuis</name>
      <address>
        <city>Antwerpen</city>
        <zip>2069</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Les Cliniques du Sud Luxembourg</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St-Jan Brugge Oostende AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ-VUB</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jules Bordet Institut</name>
      <address>
        <city>Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virga Jesse Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven, Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Hartziekenhuis Roeselare-Menen vzw campus Wilgenstraat</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires UCL de Mont-Godine</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Columbian Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3M 1X4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency - Fraser Valley Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leukemia/BMT Program of BCDiv of Hem, Vancouver Gen Hosp</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Island Cancer Center</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John Regional Hospital</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 3L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Science Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Charles LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Cite-de-la-Sante</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel-Dieu de Levis</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G5V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>G4H 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Maisonneuve - Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM- Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer B. Davis - Jewish Genl</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUQ - Hotel-Dieu de QuebecHematology - Oncology</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood Disease Hospital, Chinese Academy of Medical Science and Peking Union Medical College</name>
      <address>
        <city>Tianjin</city>
        <zip>300041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Claude BernardOncologie</name>
      <address>
        <city>Albi</city>
        <zip>81000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital du bocage</name>
      <address>
        <city>Angers cedex 01</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Argenteuil Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la cote basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Blois cedex</city>
        <zip>41016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny Cedex</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Fleyriat</name>
      <address>
        <city>Bourg en Bresse cedex</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Augustin Morvan</name>
      <address>
        <city>Brest cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen cedex 5</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Cannes Cedex</city>
        <zip>06401</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Rene Dubois</name>
      <address>
        <city>Cergy-Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier William Morey</name>
      <address>
        <city>Chalon/Saone Cedex</city>
        <zip>71321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital dinstruction des armees Percy</name>
      <address>
        <city>Clamart Cedex</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Antoine Beclere</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Louis Pasteur</name>
      <address>
        <city>Colmar cedex</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital du bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General</name>
      <address>
        <city>Dunkerque</city>
        <zip>59385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Grenoble cedex 09</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Prive de Cancerologie</name>
      <address>
        <city>Grenoble</city>
        <zip>38034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental</name>
      <address>
        <city>La Roche -Sur-Yon cedex 9</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Le Chesnay Cedex</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital J MonodRhumato Nord</name>
      <address>
        <city>Le Havre</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kremlin Bicetre</name>
      <address>
        <city>Le Kremlin bicetre CDX</city>
        <zip>942975</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Le Mans cedex</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU-Hopital Claude Huriez</name>
      <address>
        <city>Lille cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GH de Institut Catholique St Vincent</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH - Hôpital Dupuytren</name>
      <address>
        <city>Limoges Cedex 1</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital Edouard Herriot</name>
      <address>
        <city>Lyon cedex</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Valence</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Mercy</name>
      <address>
        <city>METZ cedex 3</city>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pont de chaume Oncologie et Radiotherapie</name>
      <address>
        <city>Montauban cedex</city>
        <zip>82017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Emile Muller</name>
      <address>
        <city>Mulhouse</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne Oncologie medicale et Hematologie</name>
      <address>
        <city>Nice cedex 1</city>
        <zip>06050</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de lArchet 1</name>
      <address>
        <city>Nice cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH La Source</name>
      <address>
        <city>Orleans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital St-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hopital du Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CU CHU Clemenceau</name>
      <address>
        <city>Poitiers cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital R. Debre</name>
      <address>
        <city>Reims cedex</city>
        <zip>51032</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Reims - Hôpital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital sud Medecine Interne</name>
      <address>
        <city>Rennes cedex 02</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpital de Pontchaillou</name>
      <address>
        <city>Rennes Cedex</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHG Rodez</name>
      <address>
        <city>Rodez</city>
        <zip>12027</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen cedex</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Loire</name>
      <address>
        <city>St Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Yves Le Foll</name>
      <address>
        <city>St-Brieuc cedex 1</city>
        <zip>22027</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Purpan</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>TSA 40031-31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Bretonneau</name>
      <address>
        <city>Tours cedex</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpitaux de Brabois</name>
      <address>
        <city>Vandoeuvre Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH P. Chubert</name>
      <address>
        <city>Vannes cedex</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Kinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Dusseldorf Klinik fuer Haematologie</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen-</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtische Kliniken Frankfurt am Main Hochst</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ernst-Moritz-Arndt-Universität Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Askepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinik A</name>
      <address>
        <city>Muenster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann-Wolfgang-Goethe-Universtat</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik III Klinikum der Universität München-Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultat der Universitat Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum F. Innere Medizin II Robert- Bosch-Krankenhaus GmBH</name>
      <address>
        <city>Stuttgart</city>
        <zip>D -70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik - Abteilung II</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik fur Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandra Hospital, University of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Attiko Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>124</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelismos Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metaxa Hospital Peiraias</name>
      <address>
        <city>Piraeus</city>
        <zip>18537</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theagenio Anticancer Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>540 07</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adelaide and Meath Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>24</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misercordiae Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <zip>ST46QG</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica, Università della Magna Grecia</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica, A.O.U. San Martino di Genova</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia ed Immunologia, Azienda Ospedaliera Vito Fazzi di Lecce</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Oncoematologia, Ospedale di Matera</name>
      <address>
        <city>Matera</city>
        <zip>75100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia e Trapianto di Midollo Osseo</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia - IEO</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero A. Perrino</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncoematologia, Istituto Nazionale Tumori Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura La Maddalena, Divisione di Ematologia</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Matteo Universita Di Pavia</name>
      <address>
        <city>Pavia 2</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Ospedale S.Chiara Dip.Oncologia, Div. Ematologia</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena, Struttura Complessa Ematologia ed Unita di Cellule Staminali</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Umberto I, Universita La Sapienzadi Roma</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Molinette</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center 3056-6</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hwasun Chonnam National University Hospital</name>
      <address>
        <city>Hwasun-goon</city>
        <zip>519-803</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital 42</name>
      <address>
        <city>Jeonju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seongsanno</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul - Saint Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Newtown</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sao Marcos</name>
      <address>
        <city>Braga</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitais da Universidade de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia de Lisboa</name>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Oncologia Porto</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santo Antonio- Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona (Barcelona)</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia-Hospital Duran</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>7198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra,</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau</name>
      <address>
        <city>Reus</city>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donosti</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universtario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosptial La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkoping University Hospital</name>
      <address>
        <city>Linkoping</city>
        <zip>SE 581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University HospitalSolna</name>
      <address>
        <city>Stockholm</city>
        <zip>SE 17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Görans Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE- 11281</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abteilung Onkologie Haematologie des Kantonsspitals Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitatsSpital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselsspital Bern</name>
      <address>
        <city>Berne</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubunden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Munsterlingen</name>
      <address>
        <city>Münsterlingen (TG)</city>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran General Hospital - Taipei</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Tapei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwynedd Hospital</name>
      <address>
        <city>Bangor</city>
        <zip>LL57 2PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital Haematology Department</name>
      <address>
        <city>Belfast Northern Ireland</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birminghman QE</name>
      <address>
        <city>Birmingham West Midlands</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hosp</name>
      <address>
        <city>Bournemouth Dorset</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales - Cardiff</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Beatson West of Scotland Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Haematology St Bartholomews Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' Hospital - London</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchhill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LI</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth Crownhill Devon</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinderfields General Hospital</name>
      <address>
        <city>West Yorkshire</city>
        <zip>WF1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital- Wolverhampton</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 OPQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/clinical-study-report-csr-synopses/purposes-of-posting-clinical-study-report-csr-synopses</url>
    <description>Link to CSR synopsis</description>
  </link>
  <reference>
    <citation>Dimopoulos MA, Cheung MC, Roussel M, Liu T, Gamberi B, Kolb B, Derigs HG, Eom H, Belhadj K, Lenain P, Van der Jagt R, Rigaudeau S, Dib M, Hall R, Jardel H, Jaccard A, Tosikyan A, Karlin L, Bensinger W, Schots R, Leupin N, Chen G, Marek J, Ervin-Haynes A, Facon T. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica. 2016 Mar;101(3):363-70. doi: 10.3324/haematol.2015.133629. Epub 2015 Dec 11.</citation>
    <PMID>26659916</PMID>
  </reference>
  <reference>
    <citation>Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, Song K, Rodon P, Pégourié B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. J Clin Oncol. 2016 Oct 20;34(30):3609-3617. doi: 10.1200/JCO.2016.66.7295.</citation>
    <PMID>27325857</PMID>
  </reference>
  <reference>
    <citation>Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A, Leyvraz S, Langer C, Ezaydi Y, Vogl DT, Giraldo-Castellano P, Yoon SS, Zarnitsky C, Escoffre-Barbe M, Lemieux B, Song K, Bahlis NJ, Guo S, Monzini MS, Ervin-Haynes A, Houck V, Facon T. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica. 2015 Jun;100(6):826-33. doi: 10.3324/haematol.2014.120121. Epub 2015 Mar 13.</citation>
    <PMID>25769541</PMID>
  </reference>
  <reference>
    <citation>Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551.</citation>
    <PMID>25184863</PMID>
  </reference>
  <results_reference>
    <citation>Bahlis NJ, Corso A, Mugge LO, Shen ZX, Desjardins P, Stoppa AM, Decaux O, de Revel T, Granell M, Marit G, Nahi H, Demuynck H, Huang SY, Basu S, Guthrie TH, Ervin-Haynes A, Marek J, Chen G, Facon T. Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia. 2017 Nov;31(11):2435-2442. doi: 10.1038/leu.2017.111. Epub 2017 Apr 4.</citation>
    <PMID>28373701</PMID>
  </results_reference>
  <results_reference>
    <citation>Lu J, Lee JH, Huang SY, Qiu L, Lee JJ, Liu T, Yoon SS, Kim K, Shen ZX, Eom HS, Chen WM, Min CK, Kim HJ, Lee JO, Kwak JY, Yiu W, Chen G, Ervin-Haynes A, Hulin C, Facon T. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. Br J Haematol. 2017 Mar;176(5):743-749. doi: 10.1111/bjh.14465. Epub 2017 Jan 20.</citation>
    <PMID>28106903</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <results_first_submitted>July 13, 2017</results_first_submitted>
  <results_first_submitted_qc>July 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 11, 2017</results_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>newly diagnosed multiple myeloma</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Revlimid</keyword>
  <keyword>phase III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in the Europe, Asia, North America and Pacific regions. Participants were randomized at 246 sites (165 in Europe, 23 in Asia, 39 in North America, and 19 in the Pacific). The study was co-sponsored by Intergroupe Francophone du Myélome (IFM) (for sites in France, Switzerland, and Belgium) and Celgene Corporation.</recruitment_details>
      <pre_assignment_details>Participants were stratified at randomization by 1) age (≤ 75 versus &gt; 75 years), 2) stage (International Staging System Stages I or II versus Stage III), and 3) country.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
          <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Lenalidomide and Dexamethasone Rd18</title>
          <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
        </group>
        <group group_id="P3">
          <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
          <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Active Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="535"/>
                <participants group_id="P2" count="541"/>
                <participants group_id="P3" count="547"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="532">Safety population = all randomized participants who received at least 1 dose of study treatment.</participants>
                <participants group_id="P2" count="540">Safety population = all randomized participants who received at least 1 dose of study treatment.</participants>
                <participants group_id="P3" count="541">Safety population = all randomized participants who received at least 1 dose of study treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Untreated</title>
              <participants_list>
                <participants group_id="P1" count="3">Participants randomized, but did not receive any study drug treatment.</participants>
                <participants group_id="P2" count="1">Participants randomized, but did not receive any study drug treatment.</participants>
                <participants group_id="P3" count="6">Participants randomized, but did not receive any study drug treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="535"/>
                <participants group_id="P2" count="541"/>
                <participants group_id="P3" count="547"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="76"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="273"/>
                <participants group_id="P2" count="362"/>
                <participants group_id="P3" count="339"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Close Out</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Progression Free Survival-PFS-Follow-Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87">Includes participants who discontinued treatment for reasons other than progressive disease.</participants>
                <participants group_id="P2" count="300">Includes participants who completed 18 cycles (Rd18) and did not experience progressive disease.</participants>
                <participants group_id="P3" count="273">Includes participants who completed 12 cycles MPT and did not experience progressive disease.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="300"/>
                <participants group_id="P3" count="273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Long-Term Follow Up Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="382">Includes participants from both the active treatment phase and from the PFS follow-up phase.</participants>
                <participants group_id="P2" count="463">Includes participants from both the active treatment phase and from the PFS follow-up phase.</participants>
                <participants group_id="P3" count="459">Includes participants from both the active treatment phase and from the PFS follow-up phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="255"/>
                <participants group_id="P2" count="275"/>
                <participants group_id="P3" count="315"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="188"/>
                <participants group_id="P3" count="144"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Continue in Long Term Follow Up</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="188"/>
                <participants group_id="P3" count="144"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat (ITT) population includes all participants who were randomized, independent of whether they received study treatment or not</population>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
          <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Lenalidomide and Dexamethasone Rd18</title>
          <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
          <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="535"/>
            <count group_id="B2" value="541"/>
            <count group_id="B3" value="547"/>
            <count group_id="B4" value="1623"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.2" spread="6.57"/>
                    <measurement group_id="B2" value="72.9" spread="6.50"/>
                    <measurement group_id="B3" value="73.1" spread="6.32"/>
                    <measurement group_id="B4" value="73.1" spread="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="268"/>
                    <measurement group_id="B3" value="260"/>
                    <measurement group_id="B4" value="769"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="294"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="287"/>
                    <measurement group_id="B4" value="854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islanders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="474"/>
                    <measurement group_id="B2" value="480"/>
                    <measurement group_id="B3" value="491"/>
                    <measurement group_id="B4" value="1445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, Miscellaneous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undisclosed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="493"/>
                    <measurement group_id="B2" value="505"/>
                    <measurement group_id="B3" value="508"/>
                    <measurement group_id="B4" value="1506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undisclosed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Staging System (ISS)</title>
          <description>International Staging System (ISS) is used as a staging system for multiple myeloma and divides myeloma into 3 stages based only on the serum beta-2 microglobulin and serum albumin levels. Higher stages represent more advanced disease.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="229"/>
                    <measurement group_id="B3" value="225"/>
                    <measurement group_id="B4" value="681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="219"/>
                    <measurement group_id="B4" value="627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>Eastern Cooperative Oncology Group (ECOG) Performance Status is used to assess the progress of disease in a patient, how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 (fully active)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="156"/>
                    <measurement group_id="B4" value="474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 (restrictive but ambulatory)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="257"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="275"/>
                    <measurement group_id="B4" value="795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 (ambulatory but unable to work)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-4 (limited self-care, completely disabled)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine clearance</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=60 ml/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="269"/>
                    <measurement group_id="B2" value="280"/>
                    <measurement group_id="B3" value="285"/>
                    <measurement group_id="B4" value="834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;60 ml/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="261"/>
                    <measurement group_id="B4" value="788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beta2 Microglobulin</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;5.5 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="234"/>
                    <measurement group_id="B4" value="682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=5.5 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="312"/>
                    <measurement group_id="B4" value="937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Albumin</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=35 g/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="223"/>
                    <measurement group_id="B4" value="624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 35 g/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="343"/>
                    <measurement group_id="B2" value="331"/>
                    <measurement group_id="B3" value="324"/>
                    <measurement group_id="B4" value="998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lactic Dehydrogenase</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;200 U/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="448"/>
                    <measurement group_id="B2" value="442"/>
                    <measurement group_id="B3" value="434"/>
                    <measurement group_id="B4" value="1324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=200 U/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Multiple Myeloma Subtype</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Immunoglobulin A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin A and Immunoglobulin G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin A and Immunoglobulin M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="334"/>
                    <measurement group_id="B2" value="331"/>
                    <measurement group_id="B3" value="350"/>
                    <measurement group_id="B4" value="1015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not available (includes light-chain disease)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cytogenetic Risk</title>
          <description>Cytogenetic risk categories are mutually exclusive. Definitions: Adverse risk category: t(4:14), t(14:16), del (13q) or monosomy 13, del (17p), 1q gain; Non-adverse risk categories include favorable hyperdiploidy: t(11:14), gains of 5/9/15; normal: a normal result, gains other than 5/9/15, IgH deletion, and uncertain risk: probes used for analysis cannot place participant in any risk categories. Not evaluable: no specimen received, test failure or insufficient number of cells available for analysis.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Adverse Risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="189"/>
                    <measurement group_id="B4" value="544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Favorable Hyperdiploidy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncertain Risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)</title>
        <description>PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's).</description>
        <time_frame>From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.</time_frame>
        <population>The intent to treat (ITT) population included all participants who were randomized, independent of whether they received study treatment or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)</title>
          <description>PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's).</description>
          <population>The intent to treat (ITT) population included all participants who were randomized, independent of whether they received study treatment or not.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="541"/>
                <count group_id="O3" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" lower_limit="20.7" upper_limit="29.4"/>
                    <measurement group_id="O2" value="20.7" lower_limit="19.4" upper_limit="22.0"/>
                    <measurement group_id="O3" value="21.2" lower_limit="19.3" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00006</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>Based on stratified Cox proportional hazards model comparing the hazard functions associated with treatment groups.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00001</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
            <estimate_desc>Based on stratified Cox proportional hazards model comparing the hazard functions associated with treatment groups.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.70349</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>Based on stratified Cox proportional hazards model comparing the hazard functions associated with treatment groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis</title>
        <description>PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's).</description>
        <time_frame>From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months</time_frame>
        <population>The intent to treat population included all participants who were randomized, independent of whether they received study treatment or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis</title>
          <description>PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's).</description>
          <population>The intent to treat population included all participants who were randomized, independent of whether they received study treatment or not.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="541"/>
                <count group_id="O3" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" lower_limit="20.7" upper_limit="29.7"/>
                    <measurement group_id="O2" value="21.0" lower_limit="19.7" upper_limit="22.4"/>
                    <measurement group_id="O3" value="21.9" lower_limit="19.8" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.91161</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS)</title>
        <description>Overall survival was defined as the time between randomization and death. Participants, who died, regardless of the cause of death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the participant was known to be alive.</description>
        <time_frame>From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 48.3 months</time_frame>
        <population>ITT population included all participants who were randomized, independent of whether they received study treatment or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS)</title>
          <description>Overall survival was defined as the time between randomization and death. Participants, who died, regardless of the cause of death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the participant was known to be alive.</description>
          <population>ITT population included all participants who were randomized, independent of whether they received study treatment or not.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="541"/>
                <count group_id="O3" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1" lower_limit="53.9" upper_limit="65.9"/>
                    <measurement group_id="O2" value="62.3" lower_limit="53.6" upper_limit="68.7"/>
                    <measurement group_id="O3" value="49.1" lower_limit="44.3" upper_limit="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00234</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82903</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00119</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Objective Response Based on IRAC Review</title>
        <description>Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined as: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
        <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
        <population>ITT population includes all participants who were randomized, independent of whether they received study treatment or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Objective Response Based on IRAC Review</title>
          <description>Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined as: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
          <population>ITT population includes all participants who were randomized, independent of whether they received study treatment or not.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="541"/>
                <count group_id="O3" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1"/>
                    <measurement group_id="O2" value="73.4"/>
                    <measurement group_id="O3" value="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.41</ci_lower_limit>
            <ci_upper_limit>2.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53065</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00010</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Objective Response Based on Investigator Assessment at Time of Final Analysis</title>
        <description>Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
        <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
        <population>ITT population includes all participants who were randomized, independent of whether they received study treatment or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Objective Response Based on Investigator Assessment at Time of Final Analysis</title>
          <description>Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
          <population>ITT population includes all participants who were randomized, independent of whether they received study treatment or not.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="541"/>
                <count group_id="O3" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.7"/>
                    <measurement group_id="O2" value="78.6"/>
                    <measurement group_id="O3" value="67.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.53</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40500</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00004</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.35</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimates of Duration of Myeloma Response as Determined by the IRAC</title>
        <description>Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first.</description>
        <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median follow-up for responders was 20.1 months</time_frame>
        <population>Study participants with at least a PR</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimates of Duration of Myeloma Response as Determined by the IRAC</title>
          <description>Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first.</description>
          <population>Study participants with at least a PR</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="402"/>
                <count group_id="O2" value="397"/>
                <count group_id="O3" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="27.9" upper_limit="43.4"/>
                    <measurement group_id="O2" value="22.1" lower_limit="20.3" upper_limit="24.0"/>
                    <measurement group_id="O3" value="22.3" lower_limit="20.2" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
            <estimate_desc>Based on unstratified Cox proportional hazards model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
            <estimate_desc>Based on unstratified Cox proportional hazards model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76740</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Based on unstratified Cox proportional hazards model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimates of Duration of Myeloma Response as Determined by an Investigator Assessment at Time of Final Analysis</title>
        <description>Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first.</description>
        <time_frame>Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median follow-up for responders was 19.9 months</time_frame>
        <population>Study participants with at least a PR</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimates of Duration of Myeloma Response as Determined by an Investigator Assessment at Time of Final Analysis</title>
          <description>Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first.</description>
          <population>Study participants with at least a PR</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="425"/>
                <count group_id="O3" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" lower_limit="26.2" upper_limit="37.3"/>
                    <measurement group_id="O2" value="21.5" lower_limit="19.2" upper_limit="23.0"/>
                    <measurement group_id="O3" value="22.1" lower_limit="20.3" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99537</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Response Based on the Review by the IRAC</title>
        <description>The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria.</description>
        <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
        <population>Participants who had at least a PR.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Response Based on the Review by the IRAC</title>
          <description>The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria.</description>
          <population>Participants who had at least a PR.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="402"/>
                <count group_id="O2" value="397"/>
                <count group_id="O3" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.7" upper_limit="22.2"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.8" upper_limit="17.1"/>
                    <measurement group_id="O3" value="2.8" lower_limit="1.3" upper_limit="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46672</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Response Based on the Investigator Assessment at the Time of Final Analysis</title>
        <description>The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria assessed by the investigator.</description>
        <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm.</time_frame>
        <population>Participants who had at least a PR.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Response Based on the Investigator Assessment at the Time of Final Analysis</title>
          <description>The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria assessed by the investigator.</description>
          <population>Participants who had at least a PR.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="425"/>
                <count group_id="O3" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.5" upper_limit="22.2"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.8" upper_limit="34.8"/>
                    <measurement group_id="O3" value="2.8" lower_limit="1.2" upper_limit="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46987</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimates of Time to Treatment Failure (TTF)</title>
        <description>TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by IRAC based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death.</description>
        <time_frame>From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 16.1 months.</time_frame>
        <population>ITT population includes participants who were randomized, independent of whether they received study treatment or not</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimates of Time to Treatment Failure (TTF)</title>
          <description>TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by IRAC based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death.</description>
          <population>ITT population includes participants who were randomized, independent of whether they received study treatment or not</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="541"/>
                <count group_id="O3" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="14.1" upper_limit="18.4"/>
                    <measurement group_id="O2" value="17.2" lower_limit="14.6" upper_limit="18.2"/>
                    <measurement group_id="O3" value="14.1" lower_limit="12.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00012</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00187</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45973</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimates of Time to Treatment Failure (TTF) at the Time of Final Analysis</title>
        <description>TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by the investigators assessment based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death.</description>
        <time_frame>From date of randomization until the data cut-off date of 21 January 2016; median follow up for all participants was 16.1 months.</time_frame>
        <population>ITT population includes participants who were randomized, independent of whether they received study treatment or not</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimates of Time to Treatment Failure (TTF) at the Time of Final Analysis</title>
          <description>TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by the investigators assessment based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death.</description>
          <population>ITT population includes participants who were randomized, independent of whether they received study treatment or not</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="541"/>
                <count group_id="O3" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="14.1" upper_limit="18.4"/>
                    <measurement group_id="O2" value="17.2" lower_limit="14.6" upper_limit="18.2"/>
                    <measurement group_id="O3" value="14.1" lower_limit="12.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00002</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00126</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27704</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimates for Time to Second-line Anti-myeloma Treatment (AMT)</title>
        <description>Time to second-line anti-myeloma therapy was defined as time from randomization to the start of another non-protocol anti-myeloma therapy.</description>
        <time_frame>From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 23.0 months</time_frame>
        <population>ITT population includes all participants who were randomized, independent of whether they received study treatment or not</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimates for Time to Second-line Anti-myeloma Treatment (AMT)</title>
          <description>Time to second-line anti-myeloma therapy was defined as time from randomization to the start of another non-protocol anti-myeloma therapy.</description>
          <population>ITT population includes all participants who were randomized, independent of whether they received study treatment or not</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="541"/>
                <count group_id="O3" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="32.8">Could not be estimated due to the low number of events at the time of analysis</measurement>
                    <measurement group_id="O2" value="28.5" lower_limit="26.9" upper_limit="30.4"/>
                    <measurement group_id="O3" value="26.7" lower_limit="24.0" upper_limit="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00067</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12333</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>Based on a stratified Cox proportional hazards model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimates of Time to Second Line Therapy AMT at the Time of Final Analysis</title>
        <description>Time to second-line anti-myeloma therapy is defined as time from randomization to the start of another non-protocol anti-myeloma therapy. Those who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.</description>
        <time_frame>From date of randomization until the data cut-off of date 21 January 2016; median follow-up for all participants was 23.0 months</time_frame>
        <population>ITT population includes all participants who were randomized, independent of whether they received study treatment or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimates of Time to Second Line Therapy AMT at the Time of Final Analysis</title>
          <description>Time to second-line anti-myeloma therapy is defined as time from randomization to the start of another non-protocol anti-myeloma therapy. Those who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.</description>
          <population>ITT population includes all participants who were randomized, independent of whether they received study treatment or not.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="541"/>
                <count group_id="O3" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" lower_limit="31.9" upper_limit="45.2"/>
                    <measurement group_id="O2" value="28.5" lower_limit="26.9" upper_limit="30.4"/>
                    <measurement group_id="O3" value="26.7" lower_limit="24.0" upper_limit="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>.73</ci_upper_limit>
            <estimate_desc>Based on unstratified Cox proportional hazards model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00001</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
            <estimate_desc>Based on unstratified Cox proportional hazards model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05821</p_value>
            <p_value_desc>The p-value is based on the unstratified log-rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Based on unstratified Cox proportional hazards model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Objective Response After Second-line Anti-myeloma Treatment at the Time of Final Analysis</title>
        <description>Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
        <time_frame>Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
        <population>ITT population; Participants with second line AMT.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Objective Response After Second-line Anti-myeloma Treatment at the Time of Final Analysis</title>
          <description>Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
          <population>ITT population; Participants with second line AMT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="377"/>
                <count group_id="O3" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="53.1"/>
                    <measurement group_id="O3" value="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93824</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08836</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04974</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Myeloma Response by Adverse Risk Cytogenetic Risk Category Based on IRAC Review.</title>
        <description>Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
        <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
        <population>ITT population with Cytogenetic risk of Adverse Risk</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Myeloma Response by Adverse Risk Cytogenetic Risk Category Based on IRAC Review.</title>
          <description>Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
          <population>ITT population with Cytogenetic risk of Adverse Risk</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0"/>
                    <measurement group_id="O2" value="69.7"/>
                    <measurement group_id="O3" value="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02134</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00000</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02374</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>2.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Myeloma Response by Favorable Hyperdiploidy Risk Cytogenetic Risk Category Based on IRAC Review</title>
        <description>Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
        <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
        <population>ITT population with a Cytogenetic Risk of Favorable Hyperploidy</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Myeloma Response by Favorable Hyperdiploidy Risk Cytogenetic Risk Category Based on IRAC Review</title>
          <description>Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
          <population>ITT population with a Cytogenetic Risk of Favorable Hyperploidy</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4"/>
                    <measurement group_id="O2" value="81.6"/>
                    <measurement group_id="O3" value="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11152</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>3.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86336</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07321</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>3.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Myeloma Response by Normal Risk Cytogenetic Risk Category Based on IRAC Review</title>
        <description>Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
        <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
        <population>ITT population with a cytogenetic risk of normal</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Myeloma Response by Normal Risk Cytogenetic Risk Category Based on IRAC Review</title>
          <description>Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
          <population>ITT population with a cytogenetic risk of normal</population>
          <units>percentage of particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4"/>
                    <measurement group_id="O2" value="74.8"/>
                    <measurement group_id="O3" value="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00043</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.55</ci_lower_limit>
            <ci_upper_limit>4.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31274</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01936</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>3.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Myeloma Response by Uncertain Risk Cytogenetic Risk Category Based on IRAC Review</title>
        <description>Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
        <time_frame>Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
        <population>ITT population with a Cytogenetic Risk of Uncertain Risk</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Myeloma Response by Uncertain Risk Cytogenetic Risk Category Based on IRAC Review</title>
          <description>Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.</description>
          <population>ITT population with a Cytogenetic Risk of Uncertain Risk</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5"/>
                    <measurement group_id="O2" value="76.8"/>
                    <measurement group_id="O3" value="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82128</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>2.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11041</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07302</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>5.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>Intent to Treat (ITT) population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement.</description>
          <population>Intent to Treat (ITT) population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="508"/>
                <count group_id="O2" value="507"/>
                <count group_id="O3" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="441"/>
                    <count group_id="O3" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="23.98"/>
                    <measurement group_id="O2" value="-1.3" spread="23.93"/>
                    <measurement group_id="O3" value="1.0" spread="23.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="413"/>
                    <count group_id="O3" value="396"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="24.15"/>
                    <measurement group_id="O2" value="4.7" spread="25.15"/>
                    <measurement group_id="O3" value="4.3" spread="26.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="369"/>
                    <count group_id="O2" value="376"/>
                    <count group_id="O3" value="351"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="25.93"/>
                    <measurement group_id="O2" value="5.4" spread="23.88"/>
                    <measurement group_id="O3" value="6.1" spread="25.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="302"/>
                    <count group_id="O2" value="299"/>
                    <count group_id="O3" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="26.42"/>
                    <measurement group_id="O2" value="3.2" spread="25.38"/>
                    <measurement group_id="O3" value="6.5" spread="25.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="28.02"/>
                    <measurement group_id="O2" value="5.7" spread="24.86"/>
                    <measurement group_id="O3" value="4.8" spread="27.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study discontinuation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="261"/>
                    <count group_id="O3" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="27.07"/>
                    <measurement group_id="O2" value="5.0" spread="27.33"/>
                    <measurement group_id="O3" value="0.3" spread="28.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>Intent to Treat (ITT) population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
          <population>Intent to Treat (ITT) population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="511"/>
                <count group_id="O2" value="514"/>
                <count group_id="O3" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="445"/>
                    <count group_id="O2" value="449"/>
                    <count group_id="O3" value="419"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="21.11"/>
                    <measurement group_id="O2" value="-1.4" spread="19.56"/>
                    <measurement group_id="O3" value="-0.9" spread="21.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="421"/>
                    <count group_id="O3" value="396"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="23.33"/>
                    <measurement group_id="O2" value="4.7" spread="22.94"/>
                    <measurement group_id="O3" value="2.2" spread="23.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="382"/>
                    <count group_id="O3" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="25.09"/>
                    <measurement group_id="O2" value="7.6" spread="22.85"/>
                    <measurement group_id="O3" value="5.3" spread="24.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="307"/>
                    <count group_id="O2" value="302"/>
                    <count group_id="O3" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="25.65"/>
                    <measurement group_id="O2" value="7.4" spread="23.40"/>
                    <measurement group_id="O3" value="6.9" spread="27.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                    <count group_id="O2" value="243"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="26.71"/>
                    <measurement group_id="O2" value="6.8" spread="23.58"/>
                    <measurement group_id="O3" value="8.3" spread="27.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="29.70"/>
                    <measurement group_id="O2" value="3.0" spread="27.32"/>
                    <measurement group_id="O3" value="-0.1" spread="27.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>Intent to Treat (ITT) population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
          <population>Intent to Treat (ITT) population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
                <count group_id="O2" value="508"/>
                <count group_id="O3" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="442"/>
                    <count group_id="O2" value="445"/>
                    <count group_id="O3" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="29.94"/>
                    <measurement group_id="O2" value="-4.6" spread="28.20"/>
                    <measurement group_id="O3" value="-2.4" spread="30.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="422"/>
                    <count group_id="O2" value="419"/>
                    <count group_id="O3" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="33.32"/>
                    <measurement group_id="O2" value="6.3" spread="32.43"/>
                    <measurement group_id="O3" value="4.1" spread="34.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="373"/>
                    <count group_id="O2" value="378"/>
                    <count group_id="O3" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="35.44"/>
                    <measurement group_id="O2" value="8.6" spread="32.42"/>
                    <measurement group_id="O3" value="8.2" spread="36.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="305"/>
                    <count group_id="O2" value="300"/>
                    <count group_id="O3" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="36.60"/>
                    <measurement group_id="O2" value="9.4" spread="34.15"/>
                    <measurement group_id="O3" value="11.8" spread="38.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="245"/>
                    <count group_id="O2" value="240"/>
                    <count group_id="O3" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="35.34"/>
                    <measurement group_id="O2" value="9.1" spread="34.35"/>
                    <measurement group_id="O3" value="14.5" spread="39.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="264"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="39.58"/>
                    <measurement group_id="O2" value="3.8" spread="36.34"/>
                    <measurement group_id="O3" value="-1.0" spread="38.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>Intent to Treat (ITT) population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
          <population>Intent to Treat (ITT) population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
                <count group_id="O2" value="510"/>
                <count group_id="O3" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="443"/>
                    <count group_id="O2" value="446"/>
                    <count group_id="O3" value="419"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="22.13"/>
                    <measurement group_id="O2" value="0.1" spread="20.73"/>
                    <measurement group_id="O3" value="1.0" spread="21.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="423"/>
                    <count group_id="O2" value="415"/>
                    <count group_id="O3" value="397"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="22.29"/>
                    <measurement group_id="O2" value="3.9" spread="22.11"/>
                    <measurement group_id="O3" value="2.1" spread="22.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="379"/>
                    <count group_id="O3" value="351"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="24.36"/>
                    <measurement group_id="O2" value="5.8" spread="22.39"/>
                    <measurement group_id="O3" value="5.5" spread="22.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="305"/>
                    <count group_id="O2" value="301"/>
                    <count group_id="O3" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="24.08"/>
                    <measurement group_id="O2" value="4.9" spread="22.23"/>
                    <measurement group_id="O3" value="5.1" spread="22.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="242"/>
                    <count group_id="O3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="25.61"/>
                    <measurement group_id="O2" value="3.1" spread="23.31"/>
                    <measurement group_id="O3" value="5.1" spread="22.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="24.30"/>
                    <measurement group_id="O2" value="3.7" spread="23.77"/>
                    <measurement group_id="O3" value="-0.0" spread="24.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
        <time_frame>Cycle 1 Day 1, (Baseline) then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>Intent to Treat (ITT) population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
          <population>Intent to Treat (ITT) population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
                <count group_id="O2" value="510"/>
                <count group_id="O3" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="443"/>
                    <count group_id="O2" value="447"/>
                    <count group_id="O3" value="419"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="21.73"/>
                    <measurement group_id="O2" value="-1.7" spread="19.08"/>
                    <measurement group_id="O3" value="-1.8" spread="24.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="415"/>
                    <count group_id="O3" value="397"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="22.89"/>
                    <measurement group_id="O2" value="1.8" spread="20.94"/>
                    <measurement group_id="O3" value="-1.5" spread="24.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="379"/>
                    <count group_id="O3" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="22.57"/>
                    <measurement group_id="O2" value="0.9" spread="19.77"/>
                    <measurement group_id="O3" value="-0.3" spread="23.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="301"/>
                    <count group_id="O3" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="25.05"/>
                    <measurement group_id="O2" value="-1.2" spread="20.19"/>
                    <measurement group_id="O3" value="-0.6" spread="22.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="242"/>
                    <count group_id="O3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="25.61"/>
                    <measurement group_id="O2" value="-2.8" spread="20.97"/>
                    <measurement group_id="O3" value="-0.7" spread="23.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="27.57"/>
                    <measurement group_id="O2" value="-2.6" spread="22.34"/>
                    <measurement group_id="O3" value="-7.1" spread="25.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>Intent to Treat (ITT) population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.</description>
          <population>Intent to Treat (ITT) population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="505"/>
                <count group_id="O2" value="503"/>
                <count group_id="O3" value="503"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="439"/>
                    <count group_id="O2" value="441"/>
                    <count group_id="O3" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="29.10"/>
                    <measurement group_id="O2" value="-2.2" spread="27.44"/>
                    <measurement group_id="O3" value="-1.4" spread="30.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="410"/>
                    <count group_id="O3" value="389"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="29.36"/>
                    <measurement group_id="O2" value="2.0" spread="30.93"/>
                    <measurement group_id="O3" value="2.4" spread="30.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="374"/>
                    <count group_id="O3" value="348"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="32.48"/>
                    <measurement group_id="O2" value="5.2" spread="28.50"/>
                    <measurement group_id="O3" value="3.4" spread="35.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="305"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="34.96"/>
                    <measurement group_id="O2" value="3.8" spread="32.29"/>
                    <measurement group_id="O3" value="5.8" spread="33.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                    <count group_id="O2" value="239"/>
                    <count group_id="O3" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="34.99"/>
                    <measurement group_id="O2" value="3.2" spread="31.67"/>
                    <measurement group_id="O3" value="6.0" spread="35.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="257"/>
                    <count group_id="O3" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="33.50"/>
                    <measurement group_id="O2" value="2.7" spread="33.37"/>
                    <measurement group_id="O3" value="-3.5" spread="33.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EORTC QLQ-C30 Fatigue Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation</time_frame>
        <population>Intent to Treat (ITT) population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EORTC QLQ-C30 Fatigue Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
          <population>Intent to Treat (ITT) population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="511"/>
                <count group_id="O2" value="514"/>
                <count group_id="O3" value="512"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="445"/>
                    <count group_id="O2" value="448"/>
                    <count group_id="O3" value="421"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="25.32"/>
                    <measurement group_id="O2" value="4.4" spread="24.03"/>
                    <measurement group_id="O3" value="2.8" spread="25.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="400"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="28.15"/>
                    <measurement group_id="O2" value="-3.4" spread="25.16"/>
                    <measurement group_id="O3" value="-1.8" spread="28.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="383"/>
                    <count group_id="O3" value="355"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="28.54"/>
                    <measurement group_id="O2" value="-5.9" spread="26.37"/>
                    <measurement group_id="O3" value="-4.5" spread="29.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="29.47"/>
                    <measurement group_id="O2" value="-2.3" spread="26.63"/>
                    <measurement group_id="O3" value="-3.9" spread="29.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="242"/>
                    <count group_id="O3" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="29.82"/>
                    <measurement group_id="O2" value="0.1" spread="29.12"/>
                    <measurement group_id="O3" value="-4.3" spread="30.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="258"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="29.75"/>
                    <measurement group_id="O2" value="-1.6" spread="29.11"/>
                    <measurement group_id="O3" value="2.7" spread="30.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EORTC QLQ-C30 Pain Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>Intent to Treat (ITT) population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EORTC QLQ-C30 Pain Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
          <population>Intent to Treat (ITT) population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="511"/>
                <count group_id="O2" value="514"/>
                <count group_id="O3" value="512"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="446"/>
                    <count group_id="O2" value="453"/>
                    <count group_id="O3" value="423"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="31.89"/>
                    <measurement group_id="O2" value="-4.4" spread="30.70"/>
                    <measurement group_id="O3" value="-7.8" spread="30.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="399"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.4" spread="34.28"/>
                    <measurement group_id="O2" value="-13.1" spread="32.32"/>
                    <measurement group_id="O3" value="-12.1" spread="31.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="379"/>
                    <count group_id="O2" value="384"/>
                    <count group_id="O3" value="355"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.4" spread="35.64"/>
                    <measurement group_id="O2" value="-16.1" spread="33.44"/>
                    <measurement group_id="O3" value="-13.4" spread="34.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="304"/>
                    <count group_id="O3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0" spread="36.05"/>
                    <measurement group_id="O2" value="-14.7" spread="32.34"/>
                    <measurement group_id="O3" value="-14.3" spread="32.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="242"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.4" spread="35.03"/>
                    <measurement group_id="O2" value="-12.4" spread="35.28"/>
                    <measurement group_id="O3" value="-14.7" spread="32.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="266"/>
                    <count group_id="O3" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="39.37"/>
                    <measurement group_id="O2" value="-7.9" spread="37.65"/>
                    <measurement group_id="O3" value="-6.0" spread="37.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EORTC QLQ-C30 Nausea/Vomiting Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>Intent to Treat (ITT) population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EORTC QLQ-C30 Nausea/Vomiting Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
          <population>Intent to Treat (ITT) population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="511"/>
                <count group_id="O2" value="513"/>
                <count group_id="O3" value="512"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="446"/>
                    <count group_id="O2" value="449"/>
                    <count group_id="O3" value="424"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="20.05"/>
                    <measurement group_id="O2" value="-0.5" spread="23.19"/>
                    <measurement group_id="O3" value="4.0" spread="22.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="422"/>
                    <count group_id="O3" value="399"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="19.42"/>
                    <measurement group_id="O2" value="-2.5" spread="21.92"/>
                    <measurement group_id="O3" value="-1.2" spread="19.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="377"/>
                    <count group_id="O2" value="381"/>
                    <count group_id="O3" value="355"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="18.53"/>
                    <measurement group_id="O2" value="-4.0" spread="21.52"/>
                    <measurement group_id="O3" value="-3.9" spread="19.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="302"/>
                    <count group_id="O3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="17.16"/>
                    <measurement group_id="O2" value="-3.6" spread="18.86"/>
                    <measurement group_id="O3" value="-3.9" spread="19.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="242"/>
                    <count group_id="O3" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="19.20"/>
                    <measurement group_id="O2" value="-2.7" spread="18.92"/>
                    <measurement group_id="O3" value="-3.9" spread="19.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="258"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="21.43"/>
                    <measurement group_id="O2" value="-4.2" spread="24.37"/>
                    <measurement group_id="O3" value="1.0" spread="21.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EORTC QLQ-C30 Dyspnea Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>ITT population includes all participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EORTC QLQ-C30 Dyspnea Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
          <population>ITT population includes all participants with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
                <count group_id="O2" value="508"/>
                <count group_id="O3" value="506"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="439"/>
                    <count group_id="O2" value="440"/>
                    <count group_id="O3" value="417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="30.87"/>
                    <measurement group_id="O2" value="3.6" spread="29.85"/>
                    <measurement group_id="O3" value="4.2" spread="32.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="423"/>
                    <count group_id="O2" value="417"/>
                    <count group_id="O3" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="31.87"/>
                    <measurement group_id="O2" value="-1.9" spread="29.45"/>
                    <measurement group_id="O3" value="2.0" spread="32.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="375"/>
                    <count group_id="O3" value="351"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="33.12"/>
                    <measurement group_id="O2" value="-2.9" spread="29.66"/>
                    <measurement group_id="O3" value="0.1" spread="30.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="303"/>
                    <count group_id="O2" value="294"/>
                    <count group_id="O3" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="30.97"/>
                    <measurement group_id="O2" value="-1.6" spread="29.23"/>
                    <measurement group_id="O3" value="-1.6" spread="32.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="32.73"/>
                    <measurement group_id="O2" value="2.9" spread="28.33"/>
                    <measurement group_id="O3" value="0.4" spread="32.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="37.42"/>
                    <measurement group_id="O2" value="0.8" spread="31.01"/>
                    <measurement group_id="O3" value="7.8" spread="33.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EORTC QLQ-C30 Insomnia Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>Intent to Treat (ITT) population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EORTC QLQ-C30 Insomnia Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.</description>
          <population>Intent to Treat (ITT) population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="510"/>
                <count group_id="O2" value="513"/>
                <count group_id="O3" value="511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="443"/>
                    <count group_id="O2" value="447"/>
                    <count group_id="O3" value="421"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="33.34"/>
                    <measurement group_id="O2" value="3.2" spread="34.32"/>
                    <measurement group_id="O3" value="-10.5" spread="30.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="422"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="399"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="35.11"/>
                    <measurement group_id="O2" value="-1.3" spread="33.54"/>
                    <measurement group_id="O3" value="-8.9" spread="35.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="379"/>
                    <count group_id="O2" value="382"/>
                    <count group_id="O3" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="34.84"/>
                    <measurement group_id="O2" value="-1.9" spread="31.43"/>
                    <measurement group_id="O3" value="-11.6" spread="32.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="303"/>
                    <count group_id="O2" value="300"/>
                    <count group_id="O3" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="34.78"/>
                    <measurement group_id="O2" value="1.1" spread="32.47"/>
                    <measurement group_id="O3" value="-9.6" spread="31.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="241"/>
                    <count group_id="O3" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="37.11"/>
                    <measurement group_id="O2" value="1.4" spread="35.72"/>
                    <measurement group_id="O3" value="-6.0" spread="34.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="265"/>
                    <count group_id="O3" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="36.47"/>
                    <measurement group_id="O2" value="-1.6" spread="31.27"/>
                    <measurement group_id="O3" value="-4.5" spread="36.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Scale is scored between 0 and 100, with a high score indicating a higher level of appetite loss. Negative change from Baseline values indicate improvement in appetite and positive values indicate worsening of appetite.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>ITT population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Scale is scored between 0 and 100, with a high score indicating a higher level of appetite loss. Negative change from Baseline values indicate improvement in appetite and positive values indicate worsening of appetite.</description>
          <population>ITT population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
                <count group_id="O2" value="512"/>
                <count group_id="O3" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="442"/>
                    <count group_id="O2" value="447"/>
                    <count group_id="O3" value="422"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="33.46"/>
                    <measurement group_id="O2" value="2.9" spread="31.87"/>
                    <measurement group_id="O3" value="1.0" spread="32.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="421"/>
                    <count group_id="O3" value="396"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="38.34"/>
                    <measurement group_id="O2" value="-3.3" spread="35.25"/>
                    <measurement group_id="O3" value="-6.2" spread="35.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="381"/>
                    <count group_id="O3" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="40.02"/>
                    <measurement group_id="O2" value="-8.6" spread="33.98"/>
                    <measurement group_id="O3" value="-13.5" spread="35.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="307"/>
                    <count group_id="O2" value="299"/>
                    <count group_id="O3" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="37.07"/>
                    <measurement group_id="O2" value="-6.4" spread="35.30"/>
                    <measurement group_id="O3" value="-10.5" spread="34.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="241"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="35.97"/>
                    <measurement group_id="O2" value="-5.1" spread="33.29"/>
                    <measurement group_id="O3" value="-12.2" spread="31.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="36.77"/>
                    <measurement group_id="O2" value="-7.5" spread="37.49"/>
                    <measurement group_id="O3" value="-2.6" spread="37.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EORTC QLQ-C30 Constipation Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale is scored between 0 and 100, with a high score indicating a higher level of constipation. Negative change from Baseline values indicate improvement in constipation and positive values indicate worsening of constipation.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>ITT population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EORTC QLQ-C30 Constipation Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale is scored between 0 and 100, with a high score indicating a higher level of constipation. Negative change from Baseline values indicate improvement in constipation and positive values indicate worsening of constipation.</description>
          <population>ITT population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="508"/>
                <count group_id="O2" value="511"/>
                <count group_id="O3" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="441"/>
                    <count group_id="O2" value="446"/>
                    <count group_id="O3" value="419"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="36.74"/>
                    <measurement group_id="O2" value="6.3" spread="36.18"/>
                    <measurement group_id="O3" value="18.4" spread="41.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="422"/>
                    <count group_id="O2" value="416"/>
                    <count group_id="O3" value="397"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="37.53"/>
                    <measurement group_id="O2" value="0.0" spread="37.02"/>
                    <measurement group_id="O3" value="13.9" spread="39.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="373"/>
                    <count group_id="O2" value="377"/>
                    <count group_id="O3" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="37.51"/>
                    <measurement group_id="O2" value="-5.1" spread="37.39"/>
                    <measurement group_id="O3" value="6.8" spread="40.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="304"/>
                    <count group_id="O2" value="301"/>
                    <count group_id="O3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="38.79"/>
                    <measurement group_id="O2" value="-5.2" spread="38.09"/>
                    <measurement group_id="O3" value="3.7" spread="38.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="242"/>
                    <count group_id="O3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="35.42"/>
                    <measurement group_id="O2" value="-5.9" spread="36.65"/>
                    <measurement group_id="O3" value="0.0" spread="37.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="261"/>
                    <count group_id="O3" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="39.98"/>
                    <measurement group_id="O2" value="-7.5" spread="39.20"/>
                    <measurement group_id="O3" value="-2.2" spread="38.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EORTC QLQ-C30 Diarrhea Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100, with a high score indicating a higher level of diarrhea. Negative change from Baseline values indicate improvement in diarrhea and positive values indicate worsening of diarrhea.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>ITT population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EORTC QLQ-C30 Diarrhea Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100, with a high score indicating a higher level of diarrhea. Negative change from Baseline values indicate improvement in diarrhea and positive values indicate worsening of diarrhea.</description>
          <population>ITT population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="508"/>
                <count group_id="O2" value="509"/>
                <count group_id="O3" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="444"/>
                    <count group_id="O3" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="25.53"/>
                    <measurement group_id="O2" value="2.3" spread="24.94"/>
                    <measurement group_id="O3" value="-0.6" spread="18.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="413"/>
                    <count group_id="O3" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="24.99"/>
                    <measurement group_id="O2" value="3.4" spread="27.27"/>
                    <measurement group_id="O3" value="-2.4" spread="18.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="373"/>
                    <count group_id="O2" value="376"/>
                    <count group_id="O3" value="351"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="28.36"/>
                    <measurement group_id="O2" value="6.0" spread="27.95"/>
                    <measurement group_id="O3" value="-2.2" spread="21.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="303"/>
                    <count group_id="O2" value="299"/>
                    <count group_id="O3" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="31.35"/>
                    <measurement group_id="O2" value="9.1" spread="28.74"/>
                    <measurement group_id="O3" value="-2.5" spread="17.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="241"/>
                    <count group_id="O3" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="31.20"/>
                    <measurement group_id="O2" value="10.9" spread="30.96"/>
                    <measurement group_id="O3" value="-1.7" spread="17.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="261"/>
                    <count group_id="O3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="29.56"/>
                    <measurement group_id="O2" value="6.4" spread="31.38"/>
                    <measurement group_id="O3" value="-0.5" spread="19.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EORTC QLQ-C30 Financial Difficulties Domain</title>
        <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Difficulties Scale is scored between 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicate improvement in financial difficulties and positive values indicate worsening of financial difficulties.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>ITT population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EORTC QLQ-C30 Financial Difficulties Domain</title>
          <description>The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Difficulties Scale is scored between 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicate improvement in financial difficulties and positive values indicate worsening of financial difficulties.</description>
          <population>ITT population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
                <count group_id="O2" value="504"/>
                <count group_id="O3" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="435"/>
                    <count group_id="O2" value="441"/>
                    <count group_id="O3" value="409"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="21.43"/>
                    <measurement group_id="O2" value="-0.3" spread="20.59"/>
                    <measurement group_id="O3" value="0.5" spread="22.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="413"/>
                    <count group_id="O2" value="407"/>
                    <count group_id="O3" value="388"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="23.09"/>
                    <measurement group_id="O2" value="-0.4" spread="21.88"/>
                    <measurement group_id="O3" value="1.9" spread="21.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="370"/>
                    <count group_id="O2" value="373"/>
                    <count group_id="O3" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="22.92"/>
                    <measurement group_id="O2" value="-0.3" spread="21.24"/>
                    <measurement group_id="O3" value="0.7" spread="24.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="302"/>
                    <count group_id="O2" value="299"/>
                    <count group_id="O3" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="23.99"/>
                    <measurement group_id="O2" value="1.6" spread="23.28"/>
                    <measurement group_id="O3" value="1.1" spread="23.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="239"/>
                    <count group_id="O3" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="22.23"/>
                    <measurement group_id="O2" value="1.8" spread="23.30"/>
                    <measurement group_id="O3" value="0.4" spread="21.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="255"/>
                    <count group_id="O3" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="27.19"/>
                    <measurement group_id="O2" value="0.5" spread="23.84"/>
                    <measurement group_id="O3" value="5.0" spread="24.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale</title>
        <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score indicates more severe disease symptom(s).</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>ITT population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale</title>
          <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score indicates more severe disease symptom(s).</description>
          <population>ITT population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="510"/>
                <count group_id="O2" value="512"/>
                <count group_id="O3" value="511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="442"/>
                    <count group_id="O2" value="448"/>
                    <count group_id="O3" value="421"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="18.75"/>
                    <measurement group_id="O2" value="-4.1" spread="19.37"/>
                    <measurement group_id="O3" value="-4.4" spread="19.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="422"/>
                    <count group_id="O2" value="418"/>
                    <count group_id="O3" value="396"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="21.66"/>
                    <measurement group_id="O2" value="-10.0" spread="19.97"/>
                    <measurement group_id="O3" value="-7.0" spread="20.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="381"/>
                    <count group_id="O3" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="20.89"/>
                    <measurement group_id="O2" value="-9.9" spread="20.94"/>
                    <measurement group_id="O3" value="-7.9" spread="21.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="21.74"/>
                    <measurement group_id="O2" value="-8.7" spread="20.29"/>
                    <measurement group_id="O3" value="-6.5" spread="21.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="243"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="23.50"/>
                    <measurement group_id="O2" value="-6.2" spread="23.30"/>
                    <measurement group_id="O3" value="-7.9" spread="21.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="266"/>
                    <count group_id="O3" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="24.82"/>
                    <measurement group_id="O2" value="-4.5" spread="24.90"/>
                    <measurement group_id="O3" value="-3.7" spread="23.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Side Effects Treatment Scale</title>
        <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score represents a more severe overall side effect of treatment.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>ITT population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Side Effects Treatment Scale</title>
          <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score represents a more severe overall side effect of treatment.</description>
          <population>ITT population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
                <count group_id="O2" value="511"/>
                <count group_id="O3" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="446"/>
                    <count group_id="O3" value="418"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="13.72"/>
                    <measurement group_id="O2" value="4.0" spread="14.89"/>
                    <measurement group_id="O3" value="5.6" spread="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="417"/>
                    <count group_id="O3" value="393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="15.23"/>
                    <measurement group_id="O2" value="1.2" spread="14.67"/>
                    <measurement group_id="O3" value="3.5" spread="15.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="378"/>
                    <count group_id="O3" value="351"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="15.58"/>
                    <measurement group_id="O2" value="-0.4" spread="14.39"/>
                    <measurement group_id="O3" value="2.9" spread="17.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="305"/>
                    <count group_id="O2" value="301"/>
                    <count group_id="O3" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="14.49"/>
                    <measurement group_id="O2" value="1.2" spread="16.20"/>
                    <measurement group_id="O3" value="4.7" spread="17.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                    <count group_id="O2" value="243"/>
                    <count group_id="O3" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="15.63"/>
                    <measurement group_id="O2" value="2.3" spread="17.36"/>
                    <measurement group_id="O3" value="4.3" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="258"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="15.85"/>
                    <measurement group_id="O2" value="-1.0" spread="15.81"/>
                    <measurement group_id="O3" value="3.8" spread="16.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale</title>
        <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the future perspective scale, a higher score indicates a better perspective of the future.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>ITT population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale</title>
          <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the future perspective scale, a higher score indicates a better perspective of the future.</description>
          <population>ITT population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="508"/>
                <count group_id="O3" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="443"/>
                    <count group_id="O3" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="22.17"/>
                    <measurement group_id="O2" value="3.9" spread="20.94"/>
                    <measurement group_id="O3" value="3.3" spread="23.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="416"/>
                    <count group_id="O2" value="414"/>
                    <count group_id="O3" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="23.28"/>
                    <measurement group_id="O2" value="9.2" spread="22.95"/>
                    <measurement group_id="O3" value="6.3" spread="25.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="367"/>
                    <count group_id="O2" value="377"/>
                    <count group_id="O3" value="350"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="23.67"/>
                    <measurement group_id="O2" value="12.3" spread="24.84"/>
                    <measurement group_id="O3" value="8.0" spread="25.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="303"/>
                    <count group_id="O2" value="299"/>
                    <count group_id="O3" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="21.90"/>
                    <measurement group_id="O2" value="12.1" spread="24.41"/>
                    <measurement group_id="O3" value="10.0" spread="26.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="245"/>
                    <count group_id="O2" value="239"/>
                    <count group_id="O3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="23.96"/>
                    <measurement group_id="O2" value="11.7" spread="24.76"/>
                    <measurement group_id="O3" value="9.5" spread="21.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="264"/>
                    <count group_id="O3" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="25.91"/>
                    <measurement group_id="O2" value="8.8" spread="26.71"/>
                    <measurement group_id="O3" value="3.2" spread="27.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Body Image Scale</title>
        <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the body image scale, a higher score indicates a better body image.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>ITT population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Body Image Scale</title>
          <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the body image scale, a higher score indicates a better body image.</description>
          <population>ITT population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="498"/>
                <count group_id="O3" value="504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="417"/>
                    <count group_id="O2" value="422"/>
                    <count group_id="O3" value="408"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="29.44"/>
                    <measurement group_id="O2" value="-1.5" spread="27.19"/>
                    <measurement group_id="O3" value="-1.6" spread="29.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="404"/>
                    <count group_id="O2" value="398"/>
                    <count group_id="O3" value="387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="27.54"/>
                    <measurement group_id="O2" value="0.8" spread="26.23"/>
                    <measurement group_id="O3" value="-3.0" spread="29.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="357"/>
                    <count group_id="O2" value="366"/>
                    <count group_id="O3" value="347"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="27.84"/>
                    <measurement group_id="O2" value="1.5" spread="29.72"/>
                    <measurement group_id="O3" value="-2.8" spread="33.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                    <count group_id="O2" value="284"/>
                    <count group_id="O3" value="242"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="29.60"/>
                    <measurement group_id="O2" value="-0.4" spread="31.64"/>
                    <measurement group_id="O3" value="-2.6" spread="31.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="236"/>
                    <count group_id="O2" value="227"/>
                    <count group_id="O3" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="28.09"/>
                    <measurement group_id="O2" value="-0.3" spread="31.04"/>
                    <measurement group_id="O3" value="-1.1" spread="33.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="253"/>
                    <count group_id="O3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="34.29"/>
                    <measurement group_id="O2" value="1.8" spread="30.66"/>
                    <measurement group_id="O3" value="-5.6" spread="33.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Health Utility Index Score</title>
        <description>EQ-5D is a self-administered questionnaire that assesses health-related quality of life. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where higher EQ-5D scores represent better health status. A positive change from baseline score indicates improvement in health status and better health state.</description>
        <time_frame>Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit</time_frame>
        <population>ITT population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Health Utility Index Score</title>
          <description>EQ-5D is a self-administered questionnaire that assesses health-related quality of life. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where higher EQ-5D scores represent better health status. A positive change from baseline score indicates improvement in health status and better health state.</description>
          <population>ITT population with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="490"/>
                <count group_id="O2" value="492"/>
                <count group_id="O3" value="490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="381"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.29"/>
                    <measurement group_id="O2" value="-0.0" spread="0.31"/>
                    <measurement group_id="O3" value="0.0" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="389"/>
                    <count group_id="O2" value="283"/>
                    <count group_id="O3" value="366"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.33"/>
                    <measurement group_id="O2" value="0.1" spread="0.32"/>
                    <measurement group_id="O3" value="0.1" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="341"/>
                    <count group_id="O2" value="351"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.32"/>
                    <measurement group_id="O2" value="0.1" spread="0.31"/>
                    <measurement group_id="O3" value="0.1" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="283"/>
                    <count group_id="O2" value="278"/>
                    <count group_id="O3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.33"/>
                    <measurement group_id="O2" value="0.1" spread="0.31"/>
                    <measurement group_id="O3" value="0.1" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                    <count group_id="O2" value="230"/>
                    <count group_id="O3" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.36"/>
                    <measurement group_id="O2" value="0.1" spread="0.32"/>
                    <measurement group_id="O3" value="0.1" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="186"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.40"/>
                    <measurement group_id="O2" value="0.0" spread="0.35"/>
                    <measurement group_id="O3" value="0.0" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year</title>
        <description>HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective. The rate of inpatient hospitalizations per patient year was calculated as the total number of hospitalizations divided by the total number of patient-years followed in the study period. Patient-years (PY) were calculated as the duration from baseline to last available HRQL assessment for each patient.</description>
        <time_frame>Day 1 (randomization) up to last visit completed 25 July 2016</time_frame>
        <population>Healthcare Resource Utilization not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year</title>
          <description>HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective. The rate of inpatient hospitalizations per patient year was calculated as the total number of hospitalizations divided by the total number of patient-years followed in the study period. Patient-years (PY) were calculated as the duration from baseline to last available HRQL assessment for each patient.</description>
          <population>Healthcare Resource Utilization not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs) During the Active Treatment Phase</title>
        <description>A TEAE is any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event.</description>
        <time_frame>From first dose of study drug through 28 days following the discontinuation visit from active treatment phase; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
        <population>Safety population included all participants who received at least one dose treatment dose of treatment in any arm</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) During the Active Treatment Phase</title>
          <description>A TEAE is any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event.</description>
          <population>Safety population included all participants who received at least one dose treatment dose of treatment in any arm</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="532"/>
                <count group_id="O2" value="540"/>
                <count group_id="O3" value="541"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 1 adverse event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="529"/>
                    <measurement group_id="O2" value="536"/>
                    <measurement group_id="O3" value="539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 grade (Gr) 3 or 4 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="453"/>
                    <measurement group_id="O2" value="433"/>
                    <measurement group_id="O3" value="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 grade (Gr) 5 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 serious adverse event (SAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359"/>
                    <measurement group_id="O2" value="308"/>
                    <measurement group_id="O3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 AE related to Lenalidomide/Dex/Mel/Pred/Thal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="506"/>
                    <measurement group_id="O2" value="501"/>
                    <measurement group_id="O3" value="527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 AE related to Lenalidomide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="482"/>
                    <measurement group_id="O2" value="481"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 AE related to dexamethasone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429"/>
                    <measurement group_id="O2" value="410"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 AE related to melphalan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 AE related to prednisone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 AE related to thalidomide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE related to Lenalidomide/Dex or Mel/Pred/Thal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                    <measurement group_id="O2" value="269"/>
                    <measurement group_id="O3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Gr 3 or 4 AE related to Len/Dex/Mel/Pred/Thal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373"/>
                    <measurement group_id="O2" value="326"/>
                    <measurement group_id="O3" value="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 grade 3 or 4 AE related to Lenalidomide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342"/>
                    <measurement group_id="O2" value="290"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 grade 3 or 4 AE related to dexamethasone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="177"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 grade 3 or 4 AE related to melphalan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 grade 3 or 4 AE related to prednisone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 grade 3 or 4 AE related to Thalidomide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1Gr 3 or 4 AE related to Len/Dex or Mel/Pred/Thal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Grade 5 AE related to Len/Dex/Mel/Pred/Thal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Grade 5 AE related to Lenalidomide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Grade 5 AE related to Dexamethasone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Grade 5 AE related to melphalan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Grade 5 AE related to prednisone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Grade 5 AE related to Thalidomide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 Grade 5 AE related to Len/Dex or Mel/Pred/Thal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 SAE related to Len/Dex/Mel/Pred/Thal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                    <measurement group_id="O2" value="158"/>
                    <measurement group_id="O3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 SAE related to Lenalidomide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 SAE related to dexamethasone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 SAE related to melphalan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 SAE related to prednisone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 SAE related to thalidomide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 SAE related to Len/Dex or Mel/Pred/Thal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1AE leading to Len/Dex/Mel/Pred/Thal Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to Lenalidomide withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to dexamethasone withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to melphalan withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to prednisone withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to Thalidomide withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1AE leading to Len/DexOR Mel/Pred/Thal Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1AE leading to Len/Dex/Mel/Pred/Thal reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279"/>
                    <measurement group_id="O2" value="214"/>
                    <measurement group_id="O3" value="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to Lenalidomide reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to dexamethasone reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to melphalan reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to prednisone reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to thalidomide reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1AE leading to Len/Dex or Mel/Pred/Thal reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to Rd or MPT interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368"/>
                    <measurement group_id="O2" value="321"/>
                    <measurement group_id="O3" value="419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to Lenalidomide interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353"/>
                    <measurement group_id="O2" value="301"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to dexamethasone interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319"/>
                    <measurement group_id="O2" value="280"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to melphalan interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to prednisone interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to Thalidomide interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 AE leading to Len and Dex or MPT interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="241"/>
                    <measurement group_id="O3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shift From Baseline to Most Extreme Postbaseline Value in Creatinine Clearance (CrCl) During the Active Treatment Phase</title>
        <description>Renal function was assessed for participants from baseline to the most extreme value in creatinine clearance calculated using the Cockcroft-Gault estimation.</description>
        <time_frame>Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
        <population>Safety Population with baseline and postbaseline CrCl data.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Shift From Baseline to Most Extreme Postbaseline Value in Creatinine Clearance (CrCl) During the Active Treatment Phase</title>
          <description>Renal function was assessed for participants from baseline to the most extreme value in creatinine clearance calculated using the Cockcroft-Gault estimation.</description>
          <population>Safety Population with baseline and postbaseline CrCl data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="506"/>
                <count group_id="O3" value="484"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CrCl&lt; 30 mL/min to CrCl&lt; 30 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl &lt; 30 mL/min to CrCl ≥ 30 but &lt; 50 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl &lt; 30 mL/min to CrCl ≥ 50 but &lt; 80 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl&lt; 30 mL/min to ≥ 80 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl≥ 30 but &lt; 50 mL/min to &lt; 30 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl ≥ 30 but &lt; 50 mL/min to CrCl ≥ 30 but &lt; 50 mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl ≥ 30 but &lt; 50 mL/min to CrCl ≥ 50 but &lt; 80 mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl ≥ 30 but &lt; 50 mL/min to ≥ 80 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl ≥ 50 but &lt; 80 mL to CrCl&lt; 30 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl ≥ 50 but &lt; 80 mL to CrCl ≥ 30 but &lt; 50 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl ≥ 50 but &lt; 80 mL to CrCl ≥ 50 but &lt; 80 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl ≥ 50 but &lt; 80 mL to ≥ 80 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl ≥ 80 mL/min to CrCl&lt; 30 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl ≥ 80 mL/min to CrCl ≥ 30 but &lt; 50 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl ≥ 80 mL/min to CrCl ≥ 50 but &lt; 80 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CrCl ≥ 80 mL/min to CrCl ≥ 80 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shift From Baseline to Most Extreme Postbaseline Value in Absolute Neutrophil Count During the Active Treatment Phase</title>
        <description>Neutrophil counts was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.</description>
        <time_frame>Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
        <population>Safety Population; includes participants with baseline and postbaseline absolute neutrophil laboratory test grade information</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Shift From Baseline to Most Extreme Postbaseline Value in Absolute Neutrophil Count During the Active Treatment Phase</title>
          <description>Neutrophil counts was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.</description>
          <population>Safety Population; includes participants with baseline and postbaseline absolute neutrophil laboratory test grade information</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="534"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal Baseline Grade to Normal Postbaseline Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="133"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Baseline Grade to Grade 1 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Baseline Grade to Grade 2 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Baseline Grade to Grade 3 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Baseline Grade to Grade 4 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 Baseline to Normal postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade1 Baseline to Grade 1 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 Baseline to Grade 2 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 Baseline to Grade 3 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 Baseline to Grade 4 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to normal postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to Grade 1 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to Grade 2 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to Grade 3 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to Grade 4 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Baseline to Normal postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Baseline to Grade 1 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Baseline to Grade 2 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Baseline to Grade 3 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade3 Baseline to Grade 4 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Baseline to Normal postbaseline Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Baseline to Grade 1 postbaseline Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Baseline to Grade 2 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Baseline Grade to Grade 3 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Baseline to Grade 4 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shift From Baseline to Most Extreme Postbaseline Value in Hemoglobin During the Active Treatment Phase</title>
        <description>Hemoglobin was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.</description>
        <time_frame>Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
        <population>Safety Population; Includes participants with baseline and postbaseline hemoglobin laboratory test grade information</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Shift From Baseline to Most Extreme Postbaseline Value in Hemoglobin During the Active Treatment Phase</title>
          <description>Hemoglobin was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.</description>
          <population>Safety Population; Includes participants with baseline and postbaseline hemoglobin laboratory test grade information</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="527"/>
                <count group_id="O2" value="535"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal Baseline Grade to Normal Postbaseline Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Baseline Grade to Grade 1 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Baseline Grade to Grade 2 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Baseline Grade to Grade 3 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Baseline Grade to Grade 4 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 Baseline to Normal postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 Baseline to Grade 1 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade1 Baseline to Grade 2 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="123"/>
                    <measurement group_id="O3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 Baseline to Grade 3 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 Baseline to Grade 4 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to normal postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to Grade 1 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to Grade 2 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="135"/>
                    <measurement group_id="O3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to Grade 3 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to Grade 4 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Baseline to Normal postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Baseline to Grade 1 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Baseline to Grade 2 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Baseline to Grade 3 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Baseline to Grade 4 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Baseline to Normal postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Baseline to Grade 1 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Baseline to Grade 2 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Baseline to Grade 3 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Baseline to Grade 4 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shift From Baseline to Most Extreme Postbaseline Value in Platelet Count During the Active Treatment Phase.</title>
        <description>Improvement in platelets was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.</description>
        <time_frame>Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm</time_frame>
        <population>Safety population; Includes participants with baseline and postbaseline platelet laboratory test grade information</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Shift From Baseline to Most Extreme Postbaseline Value in Platelet Count During the Active Treatment Phase.</title>
          <description>Improvement in platelets was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.</description>
          <population>Safety population; Includes participants with baseline and postbaseline platelet laboratory test grade information</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="527"/>
                <count group_id="O2" value="535"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal Baseline Grade to Normal Postbaseline Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                    <measurement group_id="O2" value="197"/>
                    <measurement group_id="O3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Baseline Grade to Grade 1 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                    <measurement group_id="O2" value="211"/>
                    <measurement group_id="O3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Baseline Grade to Grade 2 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Baseline Grade to Grade 3 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Baseline Grade to Grade 4 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade1 Baseline to Normal postbaseline Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 Baseline to Grade 1 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 Baseline to Grade 2 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 Baseline to Grade 3 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 Baseline to Grade 4 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to normal postbaseline Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to Grade 1 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to Grade 2 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to Grade 3 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Baseline to Grade 4 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Baseline to Normal postbaseline Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Baseline to Grade 1 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Baseline to Grade 2 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Baseline to Grade 3 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Baseline to Grade 4 postbaseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Infection Rate by Observing the Historical Data Compared to the Clinical Data Base</title>
        <description>Improvement of infection rate by observing historical data compared to the data within clinical database as not analyzed.</description>
        <time_frame>From randomization to 24 May 2013</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide and Dexamethasone Rd18</title>
            <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
            <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Infection Rate by Observing the Historical Data Compared to the Clinical Data Base</title>
          <description>Improvement of infection rate by observing historical data compared to the data within clinical database as not analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of treatment to at least 28 days after discontinuation of active treatment for those not continuing in the PFS phase; median duration of treatment was 80.2 weeks in the Rd arm, 72.0 weeks in the Rd18 arm and 67.1 weeks in the MPT arm.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide and Low-Dose Dexamethasone (Rd)</title>
          <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Lenalidomide and Dexamethasone (Rd18)</title>
          <description>Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those &gt; 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.</description>
        </group>
        <group group_id="E3">
          <title>Melphalan + Prednisone + Thalidomide (MPT)</title>
          <description>Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="378" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="308" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="270" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ANAEMIA HAEMOLYTIC AUTOIMMUNE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FEBRILE BONE MARROW APLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HAEMOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERVISCOSITY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOCOAGULABLE STATE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>IDIOPATHIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LYMPHADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA SUPRAVENTRICULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ATRIAL THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BRADYARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CARDIAC AMYLOIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CARDIAC FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>COR PULMONALE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DIASTOLIC DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE HEART DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>NODAL ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SINOATRIAL BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SINUS ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>THALASSAEMIA BETA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>THYROID CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLINDNESS UNILATERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CHOROIDAL DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DIABETIC RETINOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DIPLOPIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GLAUCOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OCULAR HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>UVEITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ENTEROCUTANEOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ENTEROVESICAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTRIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL MOTILITY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC EROSIVE GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HIATUS HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ILEUS PARALYTIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA STRANGULATED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>NECROTISING COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OBSTRUCTION GASTRIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ORAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RECTAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>REFLUX GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SIGMOIDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SUBILEUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TONGUE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GENERALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERPYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERTHERMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOTHERMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INJECTION SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERFORMANCE STATUS DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SPINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SYSTEMIC INFLAMMATORY RESPONSE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DRUG-INDUCED LIVER INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HEPATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERTRANSAMINASAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>AMYLOIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ANORECTAL INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ARTHRITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ATYPICAL PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BRONCHOPULMONARY ASPERGILLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BURSITIS INFECTIVE STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CAMPYLOBACTER INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DIARRHOEA INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DOUGLAS' ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>EMBOLIC PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ENDOPHTHALMITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>EPIGLOTTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FURUNCLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS SALMONELLA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HEPATITIS B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INFECTIVE TENOSYNOVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISCITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>KLEBSIELLA BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>KLEBSIELLA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>KLEBSIELLA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION PSEUDOMONAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MENINGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MENINGITIS CRYPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MENINGOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ORCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERIODONTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERIORBITAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERIORBITAL CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PNEUMOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PNEUMOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PNEUMOCYSTIS JIROVECI PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ESCHERICHIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PNEUMONIA KLEBSIELLA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PNEUMONIA LEGIONELLA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PNEUMOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PNEUMONIA VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PROSTATIC ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PSEUDOMEMBRANOUS COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PSEUDOMONAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL IMPETIGO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>STRONGYLOIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TRACHEOBRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TUBERCULOUS PLEURISY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>WHIPPLE'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ACETABULUM FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BLADDER INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CRANIOCEREBRAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FACE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FRACTURED SACRUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HEART INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INFUSION RELATED REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>JAW FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MEDICATION ERROR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MENISCUS LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PUBIS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FUME INHALATION DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>STERNAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>THORACIC VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TRANSFUSION-RELATED ACUTE LUNG INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TRAUMATIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ULNA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BIOPSY BONE MARROW ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS WORSENED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HEART RATE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PROTEIN URINE PRESENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PROTHROMBIN TIME RATIO INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TROPONIN T INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>CACHEXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FOOD INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIC HYPEROSMOLAR NONKETOTIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOPROTEINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MARASMUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>METABOLIC ALKALOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SHOCK HYPOGLYCAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TETANY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BONE LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CHONDROCALCINOSIS PYROPHOSPHATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DUPUYTREN'S CONTRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FIBROMYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GOUTY ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GOUTY TOPHUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MONARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MUSCLE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OSTEOCHONDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OSTEOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS OF JAW</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OSTEOPOROTIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PATHOLOGICAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>POLYARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SPINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SYNOVIAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>VERTEBRAL WEDGING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE LYMPHOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BLADDER TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BOWEN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BREAST CANCER IN SITU</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CANCER PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CARCINOID TUMOUR OF THE APPENDIX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CARDIAC MYXOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>COLON CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>COLON CANCER STAGE IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER STAGE III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LENTIGO MALIGNA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LEUKAEMIA PLASMACYTIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA STAGE IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MENINGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>METASTASES TO CENTRAL NERVOUS SYSTEM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>METASTATIC MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MULTIPLE MYELOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MYELODYSPLASTIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>NEOPLASM SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ORAL NEOPLASM BENIGN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PLASMACYTOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PROSTATIC ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RECTAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINE CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CANCER OF THE RENAL PELVIS AND URETER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TUMOUR FLARE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ALTERED STATE OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BRAIN STEM INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CAUDA EQUINA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>COORDINATION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DEMENTIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DYSTONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>EPIDURITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GUILLAIN-BARRE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LACUNAR INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MOTOR NEURONE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PARAPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PARAPLEGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PARKINSON'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PARKINSONISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORIMOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>POST HERPETIC NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PYRAMIDAL TRACT SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RADICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>REPETITIVE SPEECH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SPEECH DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TRANSIENT GLOBAL AMNESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TRIGEMINAL NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>VASCULAR ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AGITATED DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DEPRESSED MOOD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DISORIENTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>EUPHORIC MOOD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>IMPAIRED SELF-CARE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PRERENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>AZOTAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BLADDER PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OLIGURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>URINARY BLADDER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>EPIDIDYMITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GENITAL PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PROSTATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BRONCHIECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HAEMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PULMONARY ALVEOLAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERIAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PULMONARY HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PULMONARY INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PULMONARY THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ALKALOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACTINIC KERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ACUTE FEBRILE NEUTROPHILIC DERMATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CUTANEOUS VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DECUBITUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DERMATITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DERMATITIS EXFOLIATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>EXFOLIATIVE RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RASH ERYTHEMATOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RASH MACULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RASH PRURITIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TOXIC EPIDERMAL NECROLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>AORTIC DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ARTERIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS SUPERFICIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="523" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="532" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="532" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="237" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="191" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="219" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="325" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="132" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="233" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="210" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="282" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="248" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="205" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="163" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="153" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="220" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="213" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="115" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="191" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="532"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than one year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to ninety days; Investigator must delete confidential information before submission or defer publication to permit patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne McClain, Senior Manager, Clinical Trial Disclosure</name_or_title>
      <organization>Celgene Corporation</organization>
      <phone>888-260-1599</phone>
      <email>ClinicalTrialDisclosure@celgene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

